hematolog
chang
patient
sever
acut
respiratori
syndrom
sar
common
frequent
includ
thrombocytopenia
use
elisa
method
found
increas
thrombopoietin
tpo
level
plasma
convalesc
sar
patient
pgml
activ
sar
patient
pgml
compar
normal
control
patient
pgml
addit
plasma
activ
sar
patient
inhibitori
effect
cfumk
format
could
neutral
antibodi
experi
determin
whether
sarscov
directli
infect
hematopoiet
stem
cell
megakaryocyt
cell
incub
cell
sarscov
show
activ
infect
find
increas
tpo
level
plasma
sar
patient
provid
possibl
explan
genesi
thrombocytosi
frequent
develop
thrombocytopenia
sar
patient
sever
acut
respiratori
syndrom
sar
recent
emerg
human
diseas
caus
infect
novel
coronaviru
sarscov
sequenc
complet
genom
sarscov
determin
nucleotid
length
least
open
read
frame
genom
organ
similar
coronavirus
common
present
symptom
sar
patient
fever
chill
rigor
myalgia
cough
headach
dizzi
less
common
symptom
includ
sputum
product
sore
throat
coryza
nausea
vomit
diarrhea
hematolog
chang
patient
sar
common
exampl
thrombocytopenia
found
sar
patient
previous
platelet
count
l
document
sar
patient
n
hospit
prolong
activ
partialthromboplastin
time
greater
note
sar
patient
wherea
prothrombin
time
remain
normal
case
sar
patient
ddimer
level
also
elev
one
later
report
common
hematolog
chang
found
sar
patient
n
includ
thrombocytopenia
thrombocytosi
isol
prolong
activ
partialthromboplastin
time
mechan
coronaviru
caus
thrombocytopenia
subsequ
thrombocytosi
well
understood
neither
role
tpo
play
process
studi
tpo
level
plasma
sar
patient
effect
plasma
vitro
megakaryocytopoiesi
whether
sarscov
directli
infect
hematopoiet
stem
cell
megakaryocyt
cell
investig
plasma
collect
patient
sar
princ
wale
hospit
hong
kong
patient
divid
three
group
sar
patient
convalesc
n
activ
sar
patient
n
normal
control
patient
n
laboratori
staff
research
student
studi
approv
committe
clinic
research
institut
plasma
tpo
level
measur
elisa
kit
r
minneapoli
usa
follow
manufactur
instruct
briefli
monoclon
antibodi
specif
tpo
precoat
onto
micropl
standard
test
sampl
pipet
well
tpo
present
bound
immobil
antibodi
wash
away
unbound
substanc
enzymelink
polyclon
antibodi
specif
tpo
ad
well
follow
wash
remov
unbound
antibodyenzym
reagent
substrat
solut
ad
well
color
develop
proport
amount
tpo
bound
well
optic
densiti
well
measur
wave
length
nm
microread
biotek
instrument
winooski
usa
mononuclear
cell
cord
blood
separ
centrifug
use
ficollhypaqu
densiti
ad
plasma
clot
cultur
system
incub
plasma
sar
patient
normal
control
patient
day
megakaryocyt
coloni
stain
immunocytochem
method
use
biotinalkalin
phosphatas
detect
naphthol
asmx
phosphat
fast
red
cell
counterstain
haematoxylin
examin
invertedmicroscopi
antibodi
obtain
r
system
minneapoli
mn
human
megakaryoblast
cell
line
cell
obtain
atcc
rockvil
md
megakaryocyt
progenitor
cell
collect
human
cfumk
coloni
haematopoiet
cell
purifi
human
cord
blood
megakaryocyt
cell
cell
cultur
iscov
modifi
dulbecco
medium
imdm
fetal
calf
serum
fc
csl
australia
penicillin
uml
streptomycin
without
sarscov
day
humidifi
incub
express
sarscov
antigen
cultur
human
megakaryocyt
cell
cell
investig
immunofluoresc
method
use
serum
sarscov
patient
statist
signific
tpo
level
among
differ
group
evalu
tukeykram
hsd
honestli
signific
differ
test
anova
multipl
comparison
test
use
softwar
packag
jmp
sa
institut
cari
north
carolina
usa
data
present
mean
sd
p
valu
less
consid
statist
signific
correl
platelet
count
tpo
level
three
group
analyz
linear
regress
use
jmp
seven
patient
activ
sar
symptomat
patient
admit
princ
wale
hospit
hong
kong
acut
manag
sar
outbreak
march
may
diagnosi
serolog
confirm
fulfil
case
definit
sar
plasma
collect
laboratori
investig
store
research
use
convalesc
plasma
obtain
patient
hospit
recov
sar
viru
infect
specif
recoveri
defin
afebril
statu
least
seven
day
show
radiograph
improv
need
oxygen
supplement
least
fourteen
day
follow
onset
symptom
group
patient
chang
platelet
count
observ
activ
sar
patient
thrombocytopenia
platelet
count
recov
sar
patient
thrombocytosi
platelet
count
document
use
elisa
method
level
tpo
three
group
plasma
measur
increas
tpo
level
plasma
convalesc
sar
patient
pgml
n
p
activ
sar
patient
pgml
n
p
compar
normal
control
patient
pgml
n
fig
studi
correl
platelet
count
plasma
tpo
level
linear
regress
analys
carri
normal
convalesc
sar
activ
sar
patient
group
respect
found
correl
coeffici
r
normal
group
r
activ
sar
group
r
convalesc
sar
group
tpo
level
normal
group
invers
correl
platelet
number
r
tpo
level
activ
convalesc
sar
patient
show
posit
correl
platelet
count
studi
effect
plasma
collect
sar
patient
vitro
megakaryocytopoiesi
found
plasma
activ
sar
patient
inhibitori
effect
cfumk
format
cell
n
compar
convalesc
sar
patient
cell
n
p
normal
control
cell
n
p
previou
studi
show
increas
level
activ
sar
patient
suggest
relat
cytokin
storm
trigger
viral
infect
might
involv
inhibit
megakaryocytopoiesi
lead
thrombocytopenia
test
hypothesi
antibodi
ad
plasma
clot
cultur
system
observ
inhibitori
effect
plasma
activ
sar
plasma
cfumk
format
could
neutral
cell
n
p
antibodi
suggest
may
involv
inhibitori
process
molecular
sequenc
sarscov
detect
plasma
sar
patient
howev
remain
unknown
whether
sarscov
establish
infect
blood
cell
seven
day
incub
sarscov
viru
weak
infect
human
megakaryocyt
cell
line
cell
human
megakaryocyt
progenitor
cell
human
cell
n
could
found
fig
summari
data
support
extens
infect
blood
cell
sarscov
present
studi
show
increas
tpo
level
plasma
convalesc
sar
patient
compar
normal
control
activ
sar
patient
plasma
activ
patient
sar
also
inhibitori
effect
vitro
megakaryocytopoiesi
inhibitori
effect
could
neutral
antibodi
thu
involv
may
provid
possibl
pathophysiolog
explan
thrombocytopenia
usual
follow
thrombocytosi
sar
patient
number
mechan
control
tpo
product
propos
normal
condit
tpo
level
blood
invers
correl
number
platelet
like
due
fact
platelet
express
tpo
receptor
cmpl
figur
use
elisa
method
level
tpo
plasma
three
group
patient
detect
data
show
signific
increas
tpo
level
plasma
convalesc
sar
patient
n
p
compar
normal
control
n
shown
tpo
level
plasma
activ
sar
patient
n
normal
control
show
signific
differ
p
tpo
remov
circul
diseas
condit
product
tpo
enhanc
inflammatori
mediat
increas
tpo
transcript
product
liver
bone
marrow
stromal
cell
directli
suggest
tpo
level
influenc
product
control
platelet
number
consist
observ
also
found
increas
tpo
level
sar
patient
increas
platelet
count
plasma
increas
tpo
promot
vitro
megakaryocytopoiesi
explain
frequent
occurr
thrombocytopenia
subsequ
thrombocytosi
sar
patient
possibl
releas
relat
inhibit
recoveri
phase
activ
infect
human
megakaryocyt
cell
hematopoiet
stem
cell
incub
sarscov
studi
function
receptor
sar
coronaviru
howev
could
detect
express
human
bone
marrow
cell
platelet
megakaryocyt
cell
data
shown
might
explain
cell
infect
sar
viru
result
support
hypothesi
sarscov
may
invok
activ
infect
blood
cell
stead
demonstr
plasma
megakaryocyt
inhibitori
factor
possibl
suppress
megakaryocyt
develop
result
thrombocytopenia
sar
emerg
infect
diseas
hematolog
chang
common
elucid
mechan
coronaviru
infect
caus
cytopenia
import
better
manag
diseas
gener
viru
may
directli
infect
hematopoiet
stemprogenitor
cell
induc
growth
inhibit
apoptosi
although
unabl
observ
activ
infect
blood
cell
viru
studi
furthermor
gener
viru
infect
may
caus
immun
damag
blood
cell
induc
autoantibodi
immun
complex
case
thrombocytopenia
associ
sarscov
infect
anoth
potenti
mechan
may
also
involv
specif
lung
sar
patient
show
diffus
alveolar
damag
damag
lung
tissu
pulmonari
endotheli
cell
may
caus
activ
entrap
platelet
lung
along
thrombi
format
site
injuri
may
lead
consumpt
platelet
subsequ
addit
lung
may
also
site
platelet
releas
matur
megakayocyt
case
damag
lung
may
result
pulmonari
fibrosi
patholog
chang
affect
lung
megakaryocyt
fragment
platelet
product
taken
togeth
increas
consumpt
platelet
orand
decreas
product
platelet
may
lead
thrombocytopenia
